Test Shown To Reduce Mortality By 42% For Patients With Hospital-Acquired Enterococcus Faecium Bloodstream Infections

AdvanDx today announced that a new medical study demonstrated use of AdvanDx's PNA FISHв„ў test reduced mortality by 42% for patients with highly drug resistant Hospital-Acquired Enterococcus faecium bloodstream infections (BSI's). In addition, the study demonstrated that PNA FISH reduced the time to reporting of laboratory identification results for all enterococcal BSI's by 2.6 days and reduced time to appropriate antimicrobial therapy for E. faecium BSI's by 1.8 days.